Targeting Extrachromosomal DNA (ecDNA) in Cancer: A New Era of CHK1 Inhibition and Personalized Treatments

References

1. Mengistu B.A. Tsegaw T. Demessie Y. Getnet K. Bitew A.B. Kinde M.Z. Beirhun A.M. Mebratu A.S. Mekasha Y.T. Feleke M.G. Fenta M.D. Comprehensive review of drug resistance in mammalian cancer stem cells: implications for cancer therapy. Cancer Cell Int. 2024 24 1 406 10.1186/s12935‑024‑03558‑0 39695669
   [Google Scholar]
2. Khamidullina A.I. Abramenko Y.E. Bruter A.V. Tatarskiy V.V. Key proteins of replication stress response and cell cycle control as cancer therapy targets. Int. J. Mol. Sci. 2024 25 2 1263 10.3390/ijms25021263 38279263
   [Google Scholar]
3. Gibieža P. Petrikaitė V. The complex regulation of cytokinesis upon abscission checkpoint activation. Mol. Cancer Res. 2024 22 10 909 919 10.1158/1541‑7786.MCR‑24‑0365 39133919
   [Google Scholar]
4. Yan X. Mischel P. Chang H. Extrachromosomal DNA in cancer. Nat. Rev. Cancer 2024 24 4 261 273 10.1038/s41568‑024‑00669‑8 38409389
   [Google Scholar]
5. Tang J. Weiser N.E. Wang G. Chowdhry S. Curtis E.J. Zhao Y. Wong I.T.L. Marinov G.K. Li R. Hanoian P. Tse E. Mojica S.G. Hansen R. Plum J. Steffy A. Milutinovic S. Meyer S.T. Luebeck J. Wang Y. Zhang S. Altemose N. Curtis C. Greenleaf W.J. Bafna V. Benkovic S.J. Pinkerton A.B. Kasibhatla S. Hassig C.A. Mischel P.S. Chang H.Y. Enhancing transcription–replication conflict targets ecDNA-positive cancers. Nature 2024 635 8037 210 218 10.1038/s41586‑024‑07802‑5 39506153
   [Google Scholar]
6. Desai V.M. Kumbhar P. Kadam A.Y. Swarup J. Priya S. Jain A. Singhvi G. Exploring the therapeutic modalities of targeted treatment approach for skin carcinoma: Cutting-edge strategies and key insights. Expert Opin. Drug Deliv. 2024 21 8 1213 1233 10.1080/17425247.2024.2392799 39136542
   [Google Scholar]
7. Akinsulie O.C. Idris I. Aliyu V.A. Shahzad S. Banwo O.G. Ogunleye S.C. Olorunshola M. Okedoyin D.O. Ugwu C. Oladapo I.P. Gbadegoye J.O. Akande Q.A. Babawale P. Rostami S. Soetan K.O. The potential application of artificial intelligence in veterinary clinical practice and biomedical research. Front. Vet. Sci. 2024 11 1347550 10.3389/fvets.2024.1347550 38356661
   [Google Scholar]
8. Qian J. Liao G. Chen M. Peng R.W. Yan X. Du J. Huang R. Pan M. Lin Y. Gong X. Xu G. Zheng B. Chen C. Yang Z. Advancing cancer therapy: New frontiers in targeting DNA damage response. Front. Pharmacol. 2024 15 1474337 10.3389/fphar.2024.1474337 39372203
   [Google Scholar]
9. Tang Q. Wang X. Wang H. Zhong L. Zou D. Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer. Cancer Biol. Med. 2024 20 12 915 921 10.20892/j.issn.2095‑3941.2023.0260 38318945
   [Google Scholar]
10. Pusch F.F. Dorado García H. Xu R. Gürgen D. Bei Y. Brückner L. Röefzaad C. von Stebut J. Bardinet V. Chamorro Gonzalez R. Eggert A. Schulte J.H. Hundsdörfer P. Seifert G. Haase K. Schäfer B.W. Wachtel M. Kühl A.A. Ortiz M.V. Wengner A.M. Scheer M. Henssen A.G. Elimusertib has antitumor activity in preclinical patient-derived pediatric solid tumor models. Mol. Cancer Ther. 2024 23 4 507 519 10.1158/1535‑7163.MCT‑23‑0094 38159110
    [Google Scholar]